LOS ANGELES, November 15, 2022 /PRNewswire/ — ImaginAb Inc., a global biotechnology company focused on the development of 89Zr-crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agents and radiopharmaceutical therapy (RPT) products, today announced the signing of a new multi-year, announced non-exclusive license agreement with DynamiCure Biotechnology, a private biopharmaceutical company developing innovative therapeutic antibody candidates for the treatment of cancer, autoimmune diseases and other diseases.

Under the terms of the agreement, ImaginAb will license and supply clinical doses of its investigational CD8 ImmunoPET™ to DynamiCure Biotechnology for use in its clinical trial.

comment on announcement, IanWilsonCEO of ImaginAb said: “We are pleased that DynamiCure Biotechnology will use our CD8 ImmunoPET™ technology in its clinical trial. This license and supply agreement allows for the use of our proprietary investigational technology in additional immuno-oncology clinical trials in the hope that it will assist DynamiCure Biotechnology in the development of their novel therapeutic products.

“As we continue to invest in the development of our clinical data and global supply chain, we remain on track to receive regulatory approval for the CD8 ImmunoPET™ technology, which we hope will eventually lead to an earlier and improved therapeutic.” efficacy and outcomes for cancer patients around the world.”

About ImaginAb

ImaginAb is a revenue-generating global clinical-stage biotechnology company developing next-generation imaging and radiopharmaceutical therapy (RPT) products via its proprietary Minibody and Cys-Diabody platforms. The lead imaging agent CD8 ImmunoPET™ is currently in Phase II clinical trials and has been licensed by numerous pharmaceutical and biotech companies for imaging in their immunotherapy clinical trials, primarily in oncology.

ImaginAb’s vision is to transform patient care and help people live better, healthier lives. For more…